Skip to main content

by Dr. C.H. Weaver M.D. 2/2021

About Libtayo (cemiplimab-rwlc)

Libtayo is a fully human monoclonal antibody precision medicine know as a “checkpoint inhibitor”. Libtayo targets the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo block cancer cells from using the PD-1 pathway to suppress T-cell activation.

Lung CancerConnect 490

In a phase III clinical trial called EMPOWER-Lung 1 Libtayo was compared to platinum-doublet chemotherapy in patients with squamous or non-squamous advanced NSCLC that tested positive for PD-L1 in ≥50% of tumor cells, but not for ALK, EGFR or ROS1. The PD-1 inhibitor Libtayo® (cemiplimab) when compared to platinum-doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ≥50% PD-L1 expression in tumor cells extends overall survival and reduces the risk of death by 43% among those with confirmed PD-L1 expression of 50% or higher.

Lung Newsletter 490

Recommended Articles


The Long View-Coping with Chronic Cancer

As treatments improve cancer patients are living well with cancer for the long term

Image placeholder title

Lessons from the Chemo Room

The chemo room was a place where people came together and shared their stories.

Image placeholder title

New Year is Coming Here is 10 Ways to Reduce Your Cancer Risk!

10 Habits you can change to reduce your risk of getting cancer.

Libtayo is no yet FDA approved in the United States but undergoing review. When approved it will represent the 5th PD-1 checkpoint inhibitor approved for the treatment of NSCLC.